Vitamin D Levels and Il28B Polymorphisms are Related to Rapid Virological Response to Standard of Care in Genotype 1 Chronic Hepatitis C

Abstract

Background

Genotype 1 (G1) chronic hepatitis C (CHC) patients achieving a rapid virological response (RVR) on pegylated interferon (PEG-IFN) plus ribavirin have a high chance of sustained virological response (SVR), influenced by IL28B status, viral load, fibrosis and insulin resistance. We assessed whether 25-hydroxyvitamin D (25[OH]D) serum levels are linked to RVR and can be used together with IL28B to construct a pretreatment model to predict RVR.

Methods

A total of 117 consecutive patients with G1 CHC were evaluated by biopsy and anthropometric and metabolic measurements. 25(OH)D serum levels were measured by HPLC. IL28B rs12979860 and rs8099917 polymorphisms were also evaluated. All patients underwent antiviral therapy with PEG-IFN-α2a plus ribavirin. HCV RNA was assessed at baseline, week 4, week 12, at the end of therapy and after 6 months of follow-up.

Results

Mean ±sd 25(OH)D serum levels were 26.3 ±10.6 μg/l (range 8.0–58.0) and 31 (26.5%) patients had the rs12979860 CC polymorphism. RVR was achieved in 35 (29.9%) patients, and 32 (91.4%) of them had an SVR, compared to 26 of 82 (31.7%) without RVR. The rs12979860 CC polymorphism (OR 4.575, 95% CI 1.761, 11.889; P=0.002) and higher 25(OH)D levels (OR 1.055, 95% CI 1.010, 1.101; P=0.01) were independently associated with the achievement of RVR by multivariate analysis. The likelihood of RVR progressively increased from patients in the worst class (vitamin D<26.8 μg/l and TT/TC polymorphism; RVR 14.2%), to those with only one positive predictor (RVR 29.7% and 37.5%), and to those in the best class (vitamin D≥26.8 μg/l and rs12979860 CC polymorphism; RVR 73.3%).

Conclusions

In patients with G1 CHC, 25(OH)D serum levels and IL28B status are independently associated with the likelihood to achieve RVR and SVR. When incorporated into a pretreatment predictive model they can assist in further discriminating patients with a high likelihood of achieving RVR and SVR.

References

Hadziyannis

S.J.

, Sette

Jr. , Morgan

T.R.

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.

Fried

M.W.

, Shiffman

M.L.

, Reddy

K.R.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.

Tanaka

, Nishida

, Sugiyama

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105–1109.

Villa

, Karampatou

, Cammà

. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 2011; 140: 818–829.

Afdhal

, McHutchison

, Zeuzem

Hepatitis C pharmacogenetics: state of the art in 2010;

Hepatology 2011; 53: 336–345.

Lo Iacono

, Venezia

, Petta

The impact of insulin resistance, serum adipocytokines and visceral obesity on liver steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007; 25: 1181–1191.

Petta

, Cammà

, Di Marco

Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. Antivir Ther 2009; 14: 631–639.

Romero-Gómez

, Del Mar Viloria

, Andrade

R.J.

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636–641.

Davis

G.L.

, Wong

J.B.

, McHutchison

J.G.

, Manns

M.P.

, Harvey

, Albrecht

Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645–652.

10.

Ferenci

, Fried

M.W.

, Shiffman

M.L.

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ ribavirin. J Hepatol 2005; 43: 425–433.

11.

Zeuzem

, Buti

, Ferenci

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97–103.

12.

Ferenci

, Laferl

, Scherzer

T.M.

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451–458.

13.

M.L.

, Dai

C.Y.

, Huang

J.F.

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884–1893.

14.

Liu

C.H.

, Liu

C.J.

, Lin

C.L.

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47: 1260–1269.

15.

Mangia

, Minerva

, Bacca

Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47: 43–50.

16.

Berg

, Weich

, Teuber

Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009; 50: 369–377.

17.

, Fellay

, Thompson

A.J.

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399–401.

18.

Suppiah

, Moldovan

, Ahlenstiel

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100–1104.

19.

Tanaka

, Nishida

, Sugiyama

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105–1109.

20.

Rauch

, Kutalik

, Descombes

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338–1345.

21.

Thompson

A.J.

, Muir

A.J.

, Sulkowski

M.S.

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120–129.

22.

Jensen

D.M.

, Morgan

T.R.

, Marcellin

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954–960.

23.

Grasso

, Malfatti

, De Leo

P.D.

Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009; 51: 984–990.

24.

Schiefke

, Fach

, Wiedmann

Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 2005; 11: 1843–1847.

25.

Duarte

M.P.

, Farias

M.L.

, Coelho

H.S.

Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol 2001; 16: 1022–1027.

26.

Chen

C.C.

, Wang

S.S.

, Jeng

F.S.

, Lee

S.D.

Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis?

J Gastroenterol Hepatol 1996; 11: 417–421.

27.

Fisher

, Fisher

Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 2007; 5: 513–520.

28.

Petta

, Cammà

, Scazzone

Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51: 1158–1167.

29.

Cantorna

M.T.

, Zhu

, Froicu

, Wittke

Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004; 80 Suppl 6: 1717S–1720S.

30.

von Essen

M.R.

, Kongsbak

, Schjerling

, Olgaard

, Odum

, Geisler

Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 2010; 11: 344–349.

31.

Abu-Mouch

, Fireman

, Jarchovsky

, Assy

The beneficial effect of vitamin D combined with Peg interferon and ribavirin for chronic HCV infection. J Hepatol 2010; 52 Suppl 1: 55.

32.

Lange

C.M.

, Sarrazin

, Zeuzem

Review article: specifically targeted anti-viral therapy for hepatitis C – a new era in therapy. Aliment Pharmacol Ther 2010; 32: 14–28.

33.

American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. American Diabetes Association: Clinical Practice Recommendations 2000 Committee Report. Diabetes Care 2000; 23 Suppl 1: S4–S19.

34.

Matthews

D.R.

, Hosker

J.P.

, Rudenski

A.S.

, Naylor

B.A.

, Treacher

D.F.

, Turner

R.C.

Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.

35.

Colloredo

, Guido

, Sonzogni

, Leandro

Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239–244.

36.

Scheuer

P.J.

Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372–374.

37.

EASL International Consensus Conference on Hepatitis C, Paris, 26–27 February 1999 Consensus Statement. J Hepatol 1999 Suppl 1; 31: S3–S8.

38.

SAS Technical Report, SAS/STAT software: changes and enhancement, release 6.07. Cary, NC: SAS Institute, Inc. 1992.

39.

Cammà

, Petta

Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: looking to the future. J Hepatol 2009; 50: 648–651.